GLSI Sets Dec. 18 Annual Meeting for Director Elections, Auditor Ratification

TL;DR

**GLSI's upcoming annual meeting is a routine governance check, but the director elections are key for future strategic direction in this clinical-stage biotech.**

AI Summary

Greenwich LifeSciences, Inc. (GLSI) is holding its Annual Meeting of Stockholders on December 18, 2025, to elect five members to its Board of Directors and ratify the appointment of MaloneBailey LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025. The company has fixed October 28, 2025, as the record date for voting, with 13,854,539 shares of common stock outstanding and eligible to vote. The Board of Directors emphasizes its commitment to good corporate governance, including a separation of the CEO and Board Chair roles, held by Snehal S. Patel and David B. McWilliams, respectively. The Board also outlines its role in risk oversight, with quarterly meetings involving the CEO and senior management to discuss strategy and evaluate risks. The Audit Committee assists in specific areas of risk oversight. No specific revenue or net income figures were disclosed in this DEF 14A filing, as it primarily focuses on procedural aspects of the annual meeting and corporate governance.

Why It Matters

This DEF 14A filing outlines the foundational governance structure for Greenwich LifeSciences, Inc., impacting investor confidence through the election of its Board of Directors and the ratification of its independent auditor, MaloneBailey LLP. A stable and well-governed board is crucial for strategic direction and oversight, directly influencing the company's long-term performance and accountability to shareholders. For employees and customers, strong governance signals stability and ethical operations. In the competitive biotech landscape, transparent governance practices can differentiate GLSI, attracting and retaining investment, especially given the inherent risks in life sciences development.

Risk Assessment

Risk Level: low — The filing is a standard DEF 14A proxy statement, primarily procedural, outlining the agenda for the annual meeting on December 18, 2025. It does not introduce new operational or financial risks, but rather details the process for electing directors and ratifying auditors, which are routine corporate governance matters. The 13,854,539 shares outstanding on the October 28, 2025 record date indicate a stable shareholder base for voting.

Analyst Insight

Investors should review the biographies of the five director nominees to understand their qualifications and potential impact on Greenwich LifeSciences' strategic direction. While the auditor ratification is typically routine, shareholders should ensure MaloneBailey LLP's independence and expertise align with the company's needs. Vote your shares by December 18, 2025, to ensure your voice is heard on these governance matters.

Key Numbers

• December 18, 2025 — Annual Meeting Date (Date stockholders will vote on proposals)
• October 28, 2025 — Record Date (Date for determining stockholders entitled to vote)
• 5 — Number of Directors to Elect (Key proposal for board composition)
• 13,854,539 — Shares of Common Stock Outstanding (Total shares eligible to vote as of Record Date)
• 6,927,270 — Shares for Quorum (Majority of outstanding shares required for a quorum)
• December 31, 2025 — Fiscal Year End (Period for which MaloneBailey LLP is appointed auditor)

Key Players & Entities

• Greenwich LifeSciences, Inc. (company) — Registrant
• MaloneBailey LLP (company) — Independent registered public accounting firm
• David B. McWilliams (person) — Chairman of the Board of Directors
• Snehal S. Patel (person) — Chief Executive Officer
• U.S. Securities and Exchange Commission (regulator) — Regulatory body
• Sheppard Mullin Richter & Hampton LLP (company) — Location of Annual Meeting
• Pacific Stock Transfer Company (company) — Transfer agent

FAQ

Industry Context

Greenwich LifeSciences operates within the biotechnology and pharmaceutical sector, which is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. The industry is driven by innovation in drug discovery and development, with a focus on unmet medical needs. Companies in this space often rely on clinical trial success and subsequent regulatory approvals for market entry and revenue generation.

Regulatory Implications

As a biotechnology company, Greenwich LifeSciences is subject to stringent regulations from bodies like the U.S. Food and Drug Administration (FDA) for drug development and approval. Compliance with these regulations is critical for product viability and market access. Any delays or failures in clinical trials or regulatory submissions can have a significant impact on the company's financial performance and stock value.

What Investors Should Do

1. Review the proxy statement and vote on the proposed items.
2. Attend the Annual Meeting or vote by proxy.
3. Note the Record Date of October 28, 2025.

Key Dates

• 2025-12-18: Annual Meeting of Stockholders — Stockholders will vote on the election of directors and ratification of the independent auditor.
• 2025-10-28: Record Date — Determines which stockholders are entitled to vote at the Annual Meeting.
• 2025-12-31: Fiscal Year End — The period for which Malone Bailey LLP is appointed as the independent registered public accounting firm.
• 2025-11-03: Mailing of Notice of Internet Availability of Proxy Materials — Informs stockholders about the availability of proxy materials online and how to access them.

Glossary

DEF 14A

A filing with the SEC that provides detailed information to shareholders about matters to be voted on at an annual meeting, including director nominations, executive compensation, and auditor ratification. (This document is the primary source of information for the annual meeting and corporate governance proposals.)

Proxy Statement

A document that the SEC requires public companies to provide to shareholders before their annual meeting, containing information about the company's governance and the proposals to be voted on. (This is the core document for understanding the agenda and voting procedures for the annual meeting.)

Record Date

A specific date set by the company to determine which shareholders are eligible to vote at a shareholder meeting. (Establishes the cutoff for determining who has the right to vote on the proposals at the December 18, 2025 meeting.)

Independent Registered Public Accounting Firm

An external audit firm hired by a company to conduct an independent audit of its financial statements. (The appointment of Malone Bailey LLP for the fiscal year ending December 31, 2025, is subject to shareholder ratification.)

Board of Directors

A group of individuals elected by shareholders to oversee the management of a company and represent shareholder interests. (The election of five directors is a key agenda item for the annual meeting.)

Street Name

Refers to shares of a company's stock that are held in an account at a brokerage firm or bank on behalf of the beneficial owner. (Explains how beneficial owners, whose shares are held in street name, can vote their shares.)

Year-Over-Year Comparison

This DEF 14A filing for the 2025 Annual Meeting focuses on procedural matters and corporate governance, such as director elections and auditor ratification. Specific financial performance metrics or comparisons to prior periods are not detailed within this document, as it is a proxy statement rather than a comprehensive annual report. The filing does not provide information on revenue growth, margin changes, or new risks compared to a previous filing.

Filing Documents

• formdef14a.htm (DEF 14A) — 262KB
• 0001493152-25-020623.txt ( ) — 263KB

From the Filing

DEF 14A 1 formdef14a.htm DEF 14A UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to § 240.14a-12 Greenwich LifeSciences, Inc. (Name of Registrant as Specified in its Charter) ( Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: Fee paid previously with preliminary materials: Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: Greenwich LifeSciences, Inc. 3992 Bluebonnet Drive, Bldg 14 Stafford, TX 77477 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held on December 18, 2025 Dear Stockholders: You are cordially invited to attend the annual meeting of stockholders of Greenwich LifeSciences, Inc. to consider and act upon the following matters: 1. To elect five (5) members to our Board of Directors; 2. To ratify the appointment of MaloneBailey LLP (“ MaloneBailey ”) as our independent registered public accounting firm for the fiscal year ending December 31, 2025; and 3. To transact such other business as may properly come before the meeting or any adjournment or postponement thereof. Greenwich LifeSciences’ Board of Directors has fixed the close of business on October 28, 2025 as the record date for a determination of stockholders entitled to notice of, and to vote at, the Annual Meeting or any adjournment or postponement thereof. If You Plan to Attend Please note that space limitations make it necessary to limit attendance of the Annual Meeting to our stockholders. Registration and seating will begin at 8:30 a.m. Shares of common stock can be voted at the Annual Meeting only if the holder thereof is present in person or by valid proxy. For admission to the Annual Meeting, each stockholder may be asked to present valid picture identification, such as a driver’s license or passport, and proof of stock ownership as of the record date, such as the enclosed proxy card or a brokerage statement reflecting stock ownership. Cameras, recording devices and other electronic devices will not be permitted at the Annual Meeting, If you do not plan on attending the Annual Meeting, please vote, date and sign the enclosed proxy and return it in the business envelope provided. Even if you do plan to attend the Annual Meeting, we recommend that you vote your shares at your earliest convenience in order to ensure your representation at the Annual Meeting. Your vote is very important. Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting to Be Held on December 18, 2025 at 9:00 a.m. local time at Sheppard Mullin Richter & Hampton LLP, 30 Rockefeller Plaza, New York, NY 10012. The proxy statement and annual report to stockholders are available at http:// www.annualgeneralmeetings.com/glsi2025 /. By the Order of the Board of Directors /s/ David B. McWilliams David B. McWilliams Chairman of the Board of Directors Dated: November 3, 2025 Whether or not you expect to attend the Annual Meeting in person, we urge you to vote your shares at your earliest convenience. This will ensure the presence of a quorum at the Annual Meeting. Promptly voting your shares will save Greenwich LifeSciences the expenses and extra work of additional solicitation. An addressed envelope for which no postage is required if mailed in the United States is enclosed if you wish to vote by mail. Submitting your proxy now will not prevent you from voting your shares at the Annual Meeting if your desire to do so, as your proxy is revocable at your option. Your vote is important, so please act today! -2- Greenwich LifeSciences, Inc. 3992 Bluebonnet Drive, Bldg 14 Stafford, TX 77477 PROXY 2025 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON DECE

View Full Filing

View this DEF 14A filing on SEC EDGAR